MT-3921- Phase 2 Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury

Brief description of study

MT-3921 is an investigational monoclonal antibody therapy for patients with severe (AIS grade A-C) traumatic cervical spinal cord injury (SCIs). This study aims to compare the efficacy of MT-3921 to a placebo with regard to improving patients sensory and motor function and overall quality of life. Additionally this study aims to understand and characterize the safety and pharmacokinetic profiles of MT-3921 in the SCI population.

Participants will be identified through the following avenues: the trauma bay or NeuroICU of Penn Presbyterian Medical Center upon admission B) Arrive as transfers from outside hospitals, or C) Elect to receive care at Penn Presbyterian upon hearing about this clinical trial. Patients with recent (within 48 hours post-injury) and C4-C7 neurological level of injury (NLI) spinal cord injury (SCI) will be screened for participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
spinal cord injury
Age: Between 18 Years - 70 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 848764

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).